Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax RateTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Interest Expenses (2022 - 2025)

Arrowhead Pharmaceuticals' Interest Expenses history spans 4 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, Interest Expenses rose 3.97% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $90.2 million, up 85.52%, while the annual FY2025 figure was $89.4 million, 176.21% up from the prior year.
  • Interest Expenses reached $22.5 million in Q4 2025 per ARWR's latest filing, up from $21.7 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $24.4 million in Q2 2025 to a low of $2.8 million in Q4 2022.
  • Average Interest Expenses over 4 years is $12.5 million, with a median of $7.2 million recorded in 2024.
  • Peak YoY movement for Interest Expenses: decreased 1.24% in 2024, then soared 378.64% in 2025.
  • A 4-year view of Interest Expenses shows it stood at $2.8 million in 2022, then skyrocketed by 88.38% to $5.4 million in 2023, then soared by 303.32% to $21.6 million in 2024, then increased by 3.97% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARWR's Interest Expenses are $22.5 million (Q4 2025), $21.7 million (Q3 2025), and $24.4 million (Q2 2025).